References

Janette Greenhalgh; Adrian Bagust; Angela Boland; Kerry Dwan; Sophie Beale; Juliet Hockenhull; Christine Proudlove; Yenal Dundar; Marty Richardson; Rumona Dickson; Anna Mullard; Ernie Marshall

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Greenhalgh J, Bagust A, Boland A, et al. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jun. (Health Technology Assessment, No. 19.47.)

Cover of Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

Show details

Contents

< Prev Next >

References

1.: Cancer Research UK. Lung Cancer Key Facts. 2013. URL: www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/lung-cancer/ (accessed September 2013).
2.: Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, et al. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess 2013:17(31). 10.3310/hta17310. [PMC free article: PMC4781689] [PubMed: 23886301] [CrossRef]
3.: Royal College of Physicians (RCP). National Lung Cancer Audit: Resources. 2013. URL: www.rcplondon.ac.uk/resources/national-lung-cancer-audit (accessed September 2013).
4.: Cancer Research UK. Lung Cancer Symptoms. 2013. URL: www.cancerresearchuk.org/cancer-help/type/lung-cancer/about/lung-cancer-symptoms (accessed September 2013).
5.: National Institute for Health and Care Excellence (NICE). Erlotinib and Gefitinib for Treating Non-Small Cell Lung Cancer that has Progressed Following Prior Chemotherapy (Review of NICE Technology Appraisals 162 and 175): Final Scope. London: NICE; 2013. URL: http://guidance.nice.org.uk/TA/WaveR/138 (accessed August 2013). [PMC free article: PMC4781386] [PubMed: 26134145]
6.: National Institute for Health and Care Excellence (NICE). The Diagnosis and Treatment of Lung Cancer: CG121 (Update of NICE Clinical Guideline 24). London: NICE; 2011. URL: http://guidance.nice.org.uk/CG121/NICEGuidance/pdf/English (accessed November 2011).
7.: Union for International Cancer Control (UICC). TNM. UICC; 2013. URL: www.uicc.org/resources/tnm/about (accessed September 2013).
8.: Cancer Research UK. CancerHelp UK, Performance Status. URL: www.cancerhelp.org.uk/about-cancer/cancer-questions/performance-status (accessed February 2011).
9.: Eastern Cooperative Oncology Group (ECOG). ECOG Performance Status. 2013. URL: http://ecog.dfci.harvard.edu/general/perf_stat.html (accessed September 2013).
10.: Karnofskv DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In Mcleod CM, editor. The Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949. pp. 191–5.
11.: Health and Social Care Information Centre. National Lung Cancer Audit Report 2012. Health and Social Care Information Centre. 2012. URL: www.hqip.org.uk/assets/NCAPOP-Library/NCAPOP-2012-13/Lung-Cancer-National-Audit-Report-pub-2012.pdf (accessed March 2013).
12.: Health and Social Care Information Centre. National Lung Cancer Audit: 2011 Patient Cohort. 2012. URL: www.hscic.gov.uk/searchcatalogue?productid=10043&q=title%3a%22Lung+cancer%22&infotype=0%2fAudit&sort=Relevance&size=10&page=1#top (accessed August 2013).
13.: Cancer Research UK. Lung Cancer UK Price Tag Eclipses the Cost of Any Other Cancer. 2012. URL: www.cancerresearchuk.org/cancer-info/news/archive/pressrelease/2012-11-07-lung-cancer-price-tag (accessed September 2013).
14.: Macmillan. Living With and After Cancer. 2013. URL: www.macmillan.org.uk/HowWeCanHelp/HowWeCanHelp.aspx (accessed September 2013).
15.: National Institute for Health and Care Excellence (NICE). Lung Cancer for Adults (QS17). London: NICE; 2012. URL: http://guidance.nice.org.uk/QS17 (accessed September 2013).
16.: National Institute for Health and Care Excellence (NICE). NICE Pathways – Treatment and Palliative Care for Lung Cancer. London: NICE; 2013. URL: http://pathways.nice.org.uk/pathways/lung-cancer (accessed September 2013).
17.: National Institute for Health and Care Excellence (NICE). Gefitinib for the First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: TA192. London: NICE; 2010. URL: http://www.nice.org.uk/TA192 (accessed November 2011).
18.: National Institute for Health and Care Excellence (NICE). Erlotinib for the First-Line Treatment of Locally Advanced or Metastatic EGFR-TK Mutation-Positive Non-Small Cell Lung Cancer: TA258. London: NICE; 2012. URL: http://guidance.nice.org.uk/TA258/Guidance/pdf/English (accessed August 2013).
19.: National Institute for Health and Care Excellence (NICE). Pemetrexed for the First-Line Treatment of Non-Small Cell Lung Cancer: Technology Assessment TA181. London: NICE; 2009. URL: http://guidance.nice.org.uk/TA181/Guidance/pdf/English (accessed December 2012).
20.: National Institute for Health and Care Excellence (NICE). Pemetrexed for the Maintenance Treatment of NSCLC: Technology Assessment TA190. London: NICE; 2010. URL: www.nice.org.uk/guidance/TA190 (accessed November 2012).
21.: National Institute for Health and Care Excellence (NICE). Erlotinib for the Treatment of Non-Small Cell Lung Cancer: TA162. London: NICE; 2008. URL: http://guidance.nice.org.uk/TA162/Guidance/pdf/English (accessed March 2013).
22.: National Institute for Health and Care Excellence (NICE). Gefitinib for the Second-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Terminated Technology Appraisal No. 175. London: NICE; 2009. URL: http://publications.nice.org.uk/gefitinib-for-the-second-line-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-ta175 (accessed March 2013).
23.: National Institute for Health and Care Excellence (NICE). Pemetrexed for the Treatment of Non-Small Cell Lung Cancer: TA124. London: NICE; 2007. URL: http://guidance.nice.org.uk/TA124/Guidance/pdf/English (accessed March 2013).
24.: electronic Medicines Compendium. eMC. 2013. URL: www.medicines.org.uk/emc/default.aspx (accessed September 2013).
25.: electronic Medicines Compendium. SPC– Tarceva. 2013. URL: www.medicines.org.uk/emc/medicine/16781/SPC/Tarceva+ 25mg%2c+ 100mg+and+ 150mg+Film-Coated+Tablets/ (accessed October 2013).
26.: electronic Medicines Compendium. SPC – IRESSA. 2013. URL: www.medicines.org.uk/emc/medicine/22104/SPC/IRESSA+ 250mg+film-coated+tablets/ (accessed October 2013).
27.: Federal Register. AstraZeneca Pharmaceuticals LP; Withdrawal of Approval of a New Drug Application for IRESSA. 2012. URL: www.federalregister.gov/articles/2012/04/25/2012–9944/astrazeneca-pharmaceuticals-lp-withdrawal-of-approval-of-a-new-drug-application-for-iressa (accessed October 2013).
28.: Roche (UK) Ltd. Erlotinib for the Treatment of Non-Small Cell Lung Cancer that has Progressed Following Prior Chemotherapy – MTA submission to NICE. 2013.
29.: Joint Formulary Committee. British National Formulary (Online). London: BMJ Group and Pharmaceutical Press. 2013: URL: www.medicinescomplete.com (accessed September 2013).
30.: Centre for Reviews and Dissemination (CRD). CRD’s Guidance for Undertaking Reviews in Healthcare: Systematic Reviews. 3rd edition. York: CRD, University of York; 2009.
31.: Shepherd FA, Pereira JR, Ciuleanu T, Eng HT, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123–32. 10.1056/NEJMoa050753. [PubMed: 16014882] [CrossRef]
32.: Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012;75:82–8. 10.1016/j.lungcan.2011.05.022. [PubMed: 21684626] [CrossRef]
33.: Bhatnagar AR, Singh DP, Sharma R, Kumbhaj P. Docetaxel versus gefitinib in patients with locally advanced or metastatic NSCLC pretreated with platinum-based chemotherapy. J Thorac Oncol 2012;3:S159.
34.: Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809–18. 10.1016/S0140-6736(08)61758-4. [PubMed: 19027483] [CrossRef]
35.: Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small-cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307–14. 10.1158/1078-0432.CCR-09-1903. [PubMed: 20145166] [CrossRef]
36.: Li H, Wang X, Hua F. [Second-line treatment with gefitinib or docetaxel for advanced non-small-cell lung cancer]. Chin J Clin Oncol 2010;37:16–18.
37.: Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs 2006;17:401–9. 10.1097/01.cad.0000203381.99490.ab. [PubMed: 16549997] [CrossRef]
38.: Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244–52. 10.1200/JCO.2007.15.0185. [PubMed: 18779611] [CrossRef]
39.: Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, Von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung cancer). Lancet 2005;366:1527–37. 10.1016/S0140-6736(05)67625-8. [PubMed: 16257339] [CrossRef]
40.: Okano Y, Ando M, Asami K, Fukuda M, Nakagawa H, Ibata H, et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol: ASCO Annual Meeting Proceedings 2013;31:8006. [PubMed: 24841974]
41.: Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981–8. 10.1016/S1470-2045(13)70310-3. [PubMed: 23883922] [CrossRef]
42.: Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300–8. 10.1016/S1470-2045(11)70385-0. [PubMed: 22277837] [CrossRef]
43.: Zhu CQ, Da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada clinical trials group study BR.21. J Clin Oncol 2008;26:4268–75. 10.1200/JCO.2007.14.8924. [PubMed: 18626007] [CrossRef]
44.: Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034–42. 10.1200/JCO.2006.06.3958. [PubMed: 17075123] [CrossRef]
45.: Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744–52. 10.1200/JCO.2009.24.3030. [PubMed: 20038723] [CrossRef]
46.: AstraZeneca. NICE Multiple Technology Appraisal of Erlotinib and Gefitinib for Treating Non-Small-Cell Lung Cancer that has Progressed Following Prior Chemotherapy (Review of TA162 and TA175). Manufacturer’s submission. 2013. [PMC free article: PMC4781386] [PubMed: 26134145]
47.: National Institute for Health and Care Excellence (NICE). Erlotinib Monotherapy for Maintenance Treatment of Non-Small-Cell Lung Cancer (TA227). London: NICE; 2011. URL: www.nice.org.uk/guidance/TA227 (accessed August 2013).
48.: Joint Formulary Committee. British National Formulary (Online). London: BMJ Group and Pharmaceutical Press; 2012. URL: www.medicinescomplete.com (accessed September 2013).
49.: Hanna N, Shepherd FA, Fossella FV, Pereira JR, Demarinis F, Von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–97. 10.1200/JCO.2004.08.163. [PubMed: 15117980] [CrossRef]
50.: European Medicines Agency (EMA). IRESSA. London: EMA; 2009. URL: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/001016/human_med_000857.jsp&mid = WC0b01ac058001d124 (accessed October 2013).
51.: Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009;361:947–57. 10.1056/NEJMoa0810699. [PubMed: 19692680] [CrossRef]
52.: European Medicines Agency (EMA). Assessment Report for IRESSA. London: EMA; 2009. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001016/WC500036361.pdf (accessed October 2013).
53.: Bongers ML, Coupe VM, Jansma EP, Smit EF, Uyl-de Groot C. Cost-effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Value Health 2011;14:A451. 10.1016/j.jval.2011.08.1194. [CrossRef]
54.: Bongers ML, Coupe VM, Jansma EP, Smit EF, Uyl-de Groot CA. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics 2012;30:17–34. 10.2165/11595000-000000000-00000. [PubMed: 22201521] [CrossRef]
55.: Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, et al. Cost-effectiveness of three strategies for second-line erlotinib initiation in non-small-cell lung cancer: the ERMETIC study part 3. Eur Respir J 2012;39:172–9. 10.1183/09031936.00201210. [PubMed: 21659409] [CrossRef]
56.: Capri S, Morabito A, Carillio G, Grossi F, Longo R, Cerea G, et al. Economic evaluation of erlotinib, docetaxel and pemetrexed as second line therapy in non-small-cell lung cancer. Pharmacoeconomics Ital Res Art 2007;9:113–24. 10.1007/BF03320705. [CrossRef]
57.: Ciuleanu TE, Dediu M, Minea LN, Baculea S, Szkultecka-Debek M. Cost-effectiveness analysis of erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC) in Romania. Value Health 2010;3:A38. 10.1016/S1098-3015(10)72166-5. [CrossRef]
58.: Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol 2011;22:1805–11. 10.1093/annonc/mdq682. [PubMed: 21273345] [CrossRef]
59.: Horgan AM, Shepherd FA, Bradbury PA, Ng R, Leighl NB. Preliminary cost-consequence analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as 2nd line therapy in advanced non-small-cell lung cancer (abstract no 8110). J Clin Oncol: ASCO Annual Meeting Proceedings 2008;26:451. 10.1093/annonc/mdq682. [PubMed: 21273345] [CrossRef]
60.: Laurendeau C, Chouaid C, Florentin V, Duchon D’engenieres V, Detournay B. Cost-minimization analysis of second-line chemotherapy for nonsmall-cell lung cancer (NSCLC). Value Health 2011;14:A440. 10.1016/j.jval.2011.08.1138. [CrossRef]
61.: Nguyen TTT, Yagudina R, Kulikov A. Cost-effectiveness analysis of erlotinib versus docetaxel, pemetrexed for second-line treatment of advanced non-small-cell lung cancer in Russia. Value Health 2011;14:A450. 10.1016/j.jval.2011.08.1191. [CrossRef]
62.: Thongprasert S, Permsuwan U. Cost-effectiveness and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective. Asia Pac J Clin Oncol 2012;8:53–61. 10.1111/j.1743-7563.2012.01528.x. [PubMed: 22369444] [CrossRef]
63.: Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, et al. Cost-effectiveness of second-line chemotherapy for non-small-cell lung cancer. J Thorac Oncol 2011;6:161–8. 10.1097/JTO.0b013e318200f4c1. [PubMed: 21150465] [CrossRef]
64.: Araujo A, Parente B, Sotto-Mayor R, Teixeira E, Almodovar T, Barata F, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small-cell lung cancer (structured abstract). Rev Port Pneumol 2008;14:803–27. [PubMed: 19023496]
65.: Asukai Y, Valladares A, Camps C, Wood E, Taipale K, Arellano J, et al. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small-cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 2010;10:26. 10.1186/1471-2407-10-26. [PMC free article: PMC2841662] [PubMed: 20113499] [CrossRef]
66.: Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, et al. Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small-cell lung cancer. J Natl Cancer Inst 2010;102:298–306. 10.1093/jnci/djp518. [PubMed: 20160168] [CrossRef]
67.: Holmes J, Dunlop D, Hemmett L, Sharplin P, Bose U. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small-cell lung cancer. Pharmacoeconomics 2004;22:581–9. 10.2165/00019053-200422090-00003. [PubMed: 15209527] [CrossRef]
68.: Thongprasert S, Tinmanee S, Permsuwan U. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small-cell lung cancer from Thai payer perspective. Asia Pac J Clin Oncol 2012;8:53–61. 10.1111/j.1743-7563.2012.01528.x. [PubMed: 22369444] [CrossRef]
69.: Cromwell I, Hoek K, Melosky B, Peacock S. Erlotinib or docetaxel for second-line treatment of non-small-cell lung cancer: a real-world cost-effectiveness analysis. J Thorac Oncol 2011;6:2097–103. 10.1097/JTO.0b013e31822f657a. [PubMed: 22052223] [CrossRef]
70.: Cromwell I, Hoek K, Malfair Taylor SC, Melosky B, Peacock S. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. Lung Cancer 2012;76:472–7. 10.1016/j.lungcan.2011.12.003. [PubMed: 22226627] [CrossRef]
71.: Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res 2010;38:9–21. 10.1177/147323001003800102. [PubMed: 20233509] [CrossRef]
72.: Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002;20:1344–52. 10.1200/JCO.20.5.1344. [PubMed: 11870178] [CrossRef]
73.: Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small-cell lung cancer (NSCLC). Lung Cancer 2008;61:405–15. 10.1016/j.lungcan.2007.12.023. [PubMed: 18295368] [CrossRef]
74.: Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095–103. [PubMed: 10811675]
75.: Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non-small-cell lung cancer. Health Qual Life Outcom 2008;6:84. 10.1186/1477-7525-6-84. [PMC free article: PMC2579282] [PubMed: 18939982] [CrossRef]
76.: National Institute of Health and Care Excellence (NICE). Breast Cancer (HER2 Negative, Oestrogen Receptor Positive, Locally Advanced or Metastatic) – Everolimus (with an Aromatase Inhibitor) (TA295). London: NICE; 2013. URL: http://guidance.nice.org.uk/TA295 (accessed September 2013).
77.: National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2008. URL: www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (accessed September 2013).
78.: National Institute for Health and Care Excellence (NICE). TA296 Lung Cancer (Non-Small-Cell, Anaplastic Lymphoma Kinase Fusion Gene, Previously Treated) – Crizotinib: Guidance. London: NICE; 2013. URL: http://guidance.nice.org.uk/TA296/Guidance/pdf/English (accessed September 2013).
79.: Shaw A, D-W Kim, Nakagawa K, Seto T, Crino L, M-J Ahn, et al. Phase III Study of Crizotinib vs. Pemetrexed or Docetaxel Chemotherapy Patients with Advanced ALK Positive NSCLC (PROFILE 1007). 37th European Society for Medical Oncology Conference, Vienna, Austria, 28 September–2 October 2012.
80.: Millar DR, Corrie P, Hill M, Pulfer A. A service evaluation to compare secondary care resource use between XELOX and FOLFOX-6 regimens in the treatment of metastatic colorectal cancer (MCRC) from a UK National Health Service (NHS) perspective. Value Health 2008;11:A483. 10.1016/S1098-3015(10)66610-7. [CrossRef]
81.: Curtis L. Unit Costs of Health and Social Care. 2011. Canterbury: PSSRU, University of Kent; 2011.
82.: Department of Health. NHS Reference Costs 2011–2012. 2013. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/127115/NSRC01-2011-12xls.xls (accessed September 2013).
83.: Department of Health. Electronic Market Information Tool (eMit). 2012. URL: http://cmu.dh.gov.uk/electronic-market-information-tool-emit/ (accessed September 2013).
84.: Curtis L. Unit Costs of Health and Social Care. 2012. Canterbury: PSSRU, University of Kent; 2012.
85.: Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354–62. [PubMed: 10856094]
86.: Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) (corrected). J Clin Oncol 2003;21:2237–46. 10.1200/JCO.2003.10.038. [PubMed: 12748244] [CrossRef]
87.: Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small-cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013;119:2754–64. 10.1002/cncr.28132. [PubMed: 23661337] [CrossRef]
88.: Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003;290:2149–58. 10.1001/jama.290.16.2149. [PubMed: 14570950] [CrossRef]
89.: Lee DH, Kim SW, Suh C, Yoon HD, Yi EJ, Lee J-S, et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008;19:2039–42. 10.1093/annonc/mdn423. [PMC free article: PMC2733114] [PubMed: 18644828] [CrossRef]
90.: Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, et al. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08–01): an open-label, phase 3 trial. Cancer 2012;118:6234–42. 10.1002/cncr.27630. [PubMed: 22674612] [CrossRef]
91.: Office for National Statistics. Death Registration Summary Tables (England and Wales, 2012). 2012. URL: www.ons.gov.uk/ons/rel/vsob1/death-reg-sum-tables/2012/index.html (accessed September 2013).
92.: Maslove L, Gower NH, Spiro SG, Rudd RM, Stephens R, West P. Estimation of the additional costs of chemotherapy for patients with advanced non-small-cell lung cancer. Thorax 2005;60:564–69. 10.1136/thx.2004.039479. [PMC free article: PMC1747451] [PubMed: 15994264] [CrossRef]
93.: National Institute for Health and Care Excellence (NICE). Advanced Breast Cancer: Diagnosis and Treatment (CG81). London: NICE; 2009. URL: www.nice.org.uk/nicemedia/pdf/cg81niceguideline.pdf (accessed September 2013).
94.: Taylor DG, Carter S. Valuing Choice-Dying at Home: A Case for More Equitable Provision of High Quality Support for People who Wish to Die at Home. London: Marie Curie Cancer Care; 2004.
95.: Morgan A, Sutton A, Wailoo A. The Risk and Costs of Febrile Neutropenia in Patients with Non Small Cell Lung Cancer Treated with Docetaxel. Sheffield: NICE Decision Support Unit, ScHARR, University of Sheffield; 2007. URL: www.nicedsu.org.uk/PDFs%20of%20reports/Erlotinib%20DSU%20final%20report1.pdf (accessed 18 October 2013). [PMC free article: PMC2658551] [PubMed: 19190633]
96.: Grutters J, Joore M, Wiegman E, Langendijk J, de Ruysscher D, Hochstenbag M. Health-related quality of life in patients surviving non-small-cell lung cancer. Thorax 2010;65:903–7. 10.1136/thx.2010.136390. [PubMed: 20861294] [CrossRef]
97.: van den Hout W, Kramer G, Noordijk E, Leer JW. Cost-utility analysis of short versus long course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst 2006;98:1786–94. 10.1093/jnci/djj496. [PubMed: 17179480] [CrossRef]
98.: Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small-cell lung cancer. Lung Cancer 2008;62:374–80. 10.1016/j.lungcan.2008.03.019. [PubMed: 18467000] [CrossRef]
99.: Bianic F, Despiegel N, Cure S, Campbell J, Wang Z, Cappelleri JC, et al. Network meta-analysis of second and third-line treatments on overall response and overall survival in patients with metastatic non-small-cell lung cancer. Eur J Cancer 2011;47:S616–17. 10.1016/S0959-8049(11)72393-0. [CrossRef]
100.: Kris M, Mok T, Kim E, Douillard JY, Fukuoka M, Thatcher N. Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small-cell lung cancer. Eur J Cancer Suppl 2009;7:505–6. 10.1016/S1359-6349(09)71716-1. [CrossRef]
101.: Guo J, Ma B, Zhou H, Wang Y, Zhang Y. Gefitinib for non-small-cell lung cancer: a meta analysis. Chin J Lung Cancer 2011;14:351–7. 10.3779/j.issn.1009-3419.2011.04.09. [PMC free article: PMC5999715] [PubMed: 21496435] [CrossRef]
102.: Hawkins N, Scott DA, Woods BS, Thatcher N. Time to broaden our horizons; the case for network meta-analysis within relapsed nonsmall cell lung cancer (NSCLC). Ann Oncol 2008;19(Suppl. 8):996–1003.
103.: Jiang J, Huang L, Liang X, Zhou X, Huang R, Chu Z, et al. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol 2011;50:582–8. 10.3109/0284186X.2010.546368. [PubMed: 21190510] [CrossRef]
104.: Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012;13:107–14. 10.1016/j.cllc.2011.08.005. [PubMed: 22056888] [CrossRef]
105.: Liverpool Reviews and Implementation Group. Erlotinib and Gefitinib for Treating Non-Small Cell Lung Cancer that has Progressed Following Prior Chemotherapy (Review of NICE Technology Appraisals 162 and 175). Liverpool: Liverpool Reviews and Implementation Group; 2014. [PMC free article: PMC4781386] [PubMed: 26134145]
106.: Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 2006;17:467–72. 10.1093/annonc/mdj115. [PubMed: 16371411] [CrossRef]
107.: Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small-cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:1031–8. 10.1378/chest.129.4.1031. [PubMed: 16608954] [CrossRef]
108.: Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16:90–6. 10.1093/annonc/mdi018. [PubMed: 15598944] [CrossRef]
109.: Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs. 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996–2004. 10.1038/sj.bjc.6602241. [PMC free article: PMC2409790] [PubMed: 15558071] [CrossRef]
110.: Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small-cell lung cancer. J Thorac Oncol 2007;2:306–11. 10.1097/01.JTO.0000263713.38826.8e. [PubMed: 17409802] [CrossRef]
111.: Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A, et al. Comparison of docetaxel and docetaxel–irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 2005;16:294–9. 10.1093/annonc/mdi053. [PubMed: 15668287] [CrossRef]
112.: Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, et al. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m²) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol 2004;15:38–44. 10.1093/annonc/mdh005. [PubMed: 14679117] [CrossRef]
113.: Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 2012;30:3640–7. 10.1200/JCO.2012.42.6932. [PubMed: 22965962] [CrossRef]
114.: Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389–95. 10.1200/JCO.2005.02.3739. [PubMed: 16293869] [CrossRef]
115.: Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, et al. A randomised phase II trial of docetaxel vs. docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 2005;92:15–20. 10.1038/sj.bjc.6602268. [PMC free article: PMC2361740] [PubMed: 15597104] [CrossRef]
116.: Royal College of Physicians (RCP). Professional Organisation Statement. Multiple Technology Appraisal: Erlotinib and Gefitinib for Treating Non-Small Cell Lung Cancer that has Progressed Following Prior Chemotherapy (Review of NICE Technology Appraisals 162 and 175) [ID620]. London: RCP; 2013. [PMC free article: PMC4781386] [PubMed: 26134145]
117.: Sharma A, Lo A, Mukherji D, Burcombe R, Sevitt T, Taylor H, et al. An analysis of rate of admissions to an inpatient facility across 3 trusts in relation to the delivery of docetaxel chemotherapy in non small cell lung cancer (NSCLC). Lung Cancer 2009;63(Suppl. 1):S6. 10.1016/S0169-5002(09)70018-2. [CrossRef]

Copyright © Queen’s Printer and Controller of HMSO 2015. This work was produced by Greenhalgh et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK304029

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Greenhalgh J, Bagust A, Boland A, et al. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jun. (Health Technology Assessment, No. 19.47.) References.
PDF version of this title (1.3M)

Other titles in this collection

Health Technology Assessment

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

References - Erlotinib and gefitinib for treating non-small cell lung cancer tha...
References - Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

References

Views

Other titles in this collection

Related information

Recent Activity